SCHEMBL5878869

SCHEMBL5878869

CC(C)(C)NC[C@@H](O)CO

nearest known ligand 0.75

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL283339 1.00 CYP2D6 (0.44) CYP2D6
SCHEMBL283340 1.00 CYP2D6 (0.44) CYP2D6
SCHEMBL7063746 0.86 CYP2D6 (0.48) CYP2D6
SCHEMBL11751768 0.80 PKM (0.41)
SCHEMBL22851451 0.80 THRB (0.42)
SCHEMBL11383973 0.80 LMNA (0.36)
SCHEMBL2245340 0.79 CYP2D6 (0.44) CYP2D6
SCHEMBL21587527 0.78 ADRB3 (0.40)
SCHEMBL4147093 0.78 ALDH1A1 (0.35)
SCHEMBL24192869 0.77 CYP2D6 (0.43) CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116203006-B Multichannel fluorescent array sensor and construction and use method thereof 中国药科大学 2025-04-25 CN claimed
CN-118580804-A Water-based binder and application thereof in hard carbon negative electrode of sodium ion battery 郑州大学 2024-09-03 CN claimed
CN-116203006-A Multichannel fluorescent array sensor and construction and use method thereof 中国药科大学 2023-06-02 CN claimed
WO-1998007653-A1 CHIRAL HYDRIDE COMPLEXES ZEELAND CHEMICALS, INC. (US) 1998-02-26 WO claimed
US-20250304726-A1 NITRIC OXIDE-RELEASING GLYCOSAMINOGLYCANS FOR WOUND HEALING THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2025-10-02 US disclosed
US-20250230406-A1 CORNEAL ENDOTHELIAL CELL PREPARATION CONTAINING NO CULTURE-DERIVED COMPONENT, AND METHOD FOR PRODUCING SAME THE DOSHISHA (JP) 2025-07-17 US disclosed
WO-2025125099-A1 HIGHLY SELECTIVE DIALYSIS MEMBRANES AND METHODS FOR PREPARING SAME GAMBRO LUNDIA AB (SE) 2025-06-19 WO disclosed
EP-4570364-A1 HIGHLY SELECTIVE DIALYSIS MEMBRANES AND METHODS FOR PREPARING SAME Gambro Lundia AB (SE) 2025-06-18 EP disclosed
CN-116203006-B Multichannel fluorescent array sensor and construction and use method thereof 中国药科大学 2025-04-25 CN disclosed
EP-4501337-A1 CORNEAL ENDOTHELIAL CELL PREPARATION CONTAINING NO CULTURE-DERIVED COMPONENT, AND METHOD FOR PRODUCING SAME The Doshisha (JP) 2025-02-05 EP disclosed
WO-2024179533-A1 AQUEOUS BINDER AND USE THEREOF IN HARD CARBON NEGATIVE ELECTRODE OF SODIUM-ION BATTERY 郑州大学 2024-09-06 WO disclosed
CN-118580804-A Water-based binder and application thereof in hard carbon negative electrode of sodium ion battery 郑州大学 2024-09-03 CN disclosed
US-20040186161-A1 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives SUGEN, INC. 2004-09-23 US disclosed
US-20030100555-A1 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives SUGEN. INC. 2003-05-29 US disclosed
US-6090950-A Chiral hydride complexes ZEELAND CHEMICALS, INC. (US) 2000-07-18 US disclosed
WO-1998007653-A1 CHIRAL HYDRIDE COMPLEXES ZEELAND CHEMICALS, INC. (US) 1998-02-26 WO disclosed
US-4521414-A 1-TERT-BUTYLAMINO-3-((4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)OXY)-2 -PROPANOL AND SALTS THERFOF THE TEXAS A&M UNIVERSITY SYSTEM (US) 1985-06-04 US disclosed
EP-0105996-A1 Ophthalmic compositions for treating elevated intraocular pressure MERCK & CO. INC. (US) 1984-04-25 EP disclosed
US-4097490-A Pyroglutamic acid salts of t-butylamino-2,3-dihydroxypropane MERCK & CO., INC. (US) 1978-06-27 US disclosed
US-3998835-A HYPERLIPOIDEMIA AND HYPERGLYCEMIA INHIBITORS, ANTIARRYHTHMIC AGENTS SANDOZ LTD. (CH) 1976-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186161-A1 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives PLK2, CDK2, PDPK1 CYP2D6 1461/4885
US-20030100555-A1 Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives PLK2, CDK2, PDPK1 CYP2D6 1461/4885
US-20250304726-A1 NITRIC OXIDE-RELEASING GLYCOSAMINOGLYCANS FOR WOUND HEALING NOS2, NOS3, NOS1 CYP2D6 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.